Ending hepatitis C

Where it stands as of Oct 15, 2026

The RESOLVE trial, published in The Lancet and led by Dr Rakesh Aggarwal, found eight weeks of sofosbuvir-velpatasvir cleared hepatitis C in 410 of 415 people who returned for testing (98.8 percent), against 397 of 401 on the standard twelve weeks (99.0 percent). It enrolled 880 untreated adults without cirrhosis at five Indian hospitals, and guidelines have not changed. People with cirrhosis, HIV or injection drug use were not studied, and whether shorter courses improve completion is not yet measured.